Kibion
Private Company
Funding information not available
Overview
Kibion is a global leader in the Helicobacter pylori diagnostics market, offering a vertically integrated solution that combines proprietary UBT kits with specialized IRIS™ breath analysis instruments. Founded in 2005 as a subsidiary of Orexo AB, the company transformed through the acquisition of Wagner Analysen Technik GmbH in 2011 and was later acquired by Mayoly Spindler in 2016, solidifying its position within a larger healthcare group. Its business model is focused on diagnostics, with a commercial-stage product portfolio sold in over 50 countries, targeting hospitals, laboratories, and clinics.
Technology Platform
Integrated Urea Breath Test (UBT) system utilizing 13C-labeled urea and proprietary IRIS™ infrared spectroscopy instruments for non-invasive detection of Helicobacter pylori.
Opportunities
Risk Factors
Competitive Landscape
Kibion competes in the H. pylori diagnostics market against other UBT kit manufacturers, stool antigen test providers, and serology assays. Its key competitive advantage is its vertically integrated 'complete solution' of kits and proprietary analyzers, targeting the laboratory and hospital segment for high accuracy and throughput.